MAP2K7 and hairy cell leukemia: Identification, further functional characterization, and reporting of more HCL patients with non-canonical mutations and rearrangements are required to better understand how they disrupt the individual components of the RAS-RAF-MEK-MAPK signaling pathway and provide an opportunity for rationalized selection of inhibitors.